Sonnet BioTherapeutics Holdings, Inc. Announces Stockholder Approval of Proposed Business Combination with Hyperliquid Strategies Inc

PRINCETON, N.J., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc., (NASDAQ: SONN) (“Sonnet” or the “Company”) today announced that its stockholders approved, among other things, the proposed business combination with Hyperliquid Strategies Inc (“HSI”) and Rorschach I LLC at its special meeting of stockholders. The final voting results for the special meeting will be filed in a Form 8-K with the U.S. Securities and Exchange Commission. About Sonnet BioTherapeutics Holdings, Inc. Sonnet ...